Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
Annette F Okai, Lilyana Amezcua, Regina R Berkovich, Angel R Chinea, Keith R Edwards, Brian Steingo, Aljoeson Walker, Alan K Jacobs, Nadia Daizadeh, Mitzi J Williams, CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators, Annette F Okai, Lilyana Amezcua, Regina R Berkovich, Angel R Chinea, Keith R Edwards, Brian Steingo, Aljoeson Walker, Alan K Jacobs, Nadia Daizadeh, Mitzi J Williams, CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators
Abstract
Introduction: Multiple sclerosis (MS) patients of African descent have increased risk for disease progression and may be less responsive to disease-modifying therapy.
Methods: Patients in the CARE-MS studies received alemtuzumab 12 mg/day [initial alemtuzumab treatment (IAT); baseline: 5 days; 12 months later: 3 days] or subcutaneous interferon beta-1a (SC IFNB-1a) 3 ×/week. Core study outcomes were compared between treatment groups. In the extension study CAMMS03409, SC IFNB-1a-treated patients switched to alemtuzumab [delayed alemtuzumab treatment (DAT)]. Data from IAT and DAT arms were pooled to assess outcomes through 6 years post alemtuzumab initiation; IAT patients had an additional 2 years of follow-up in TOPAZ.
Results: Of 1200 CARE-MS patients, 43 (4%) were of African descent (35 IAT; 8 DAT) and received alemtuzumab in the 2-year core and/or 6-year extension; 29 (67%) remained on study at the time of analysis (24 IAT patients completed year 8 post alemtuzumab; 5 DAT patients completed year 6 post alemtuzumab). In year 2, annualized relapse rate (ARR; 0.09 versus 0.42), percentage of patients with improved Expanded Disability Status Scale (EDSS; 18% versus 11%), 6-month confirmed disability improvement (CDI; 28% versus 13%), no evidence of disease activity (55% versus 13%), and cumulative brain volume loss (BVL; - 0.55% versus - 1.32%) favored alemtuzumab versus SC IFNB-1a. Alemtuzumab remained efficacious at year 6 (pooled IAT/DAT) and at year 8 (IAT only) post alemtuzumab (ARR: 0.15 and 0.30; improved EDSS: 17% and 25%; CDI: 47% and 55%; BVL: - 1.14% and - 0.70%, respectively). No safety signals were unique to this population.
Conclusions: Alemtuzumab was efficacious in a small cohort of relapsing-remitting MS patients of African descent over 8 years. Safety was consistent with the overall CARE-MS population, although the small sample size may have prevented the detection of known low-frequency adverse events. CLINICALTRIALS.
Gov registration numbers: CARE-MS I, II, extension, TOPAZ: NCT00530348, NCT00548405, NCT00930553, NCT02255656.
Funding: Sanofi (Cambridge, MA, USA) and Bayer HealthCare Pharmaceuticals (Leverkusen, Germany).
Keywords: African descent; Alemtuzumab; Disease-modifying therapy; Multiple sclerosis.
Figures
References
- Ferreira Vasconcelos CC, Cruz Dos Santos GA, Thuler LC, Camargo SM, Papais Alvarenga RM. African ancestry is a predictor factor to secondary progression in clinical course of multiple sclerosis. ISRN Neurol. 2012; 2012:410629.
- Cree BA, Khan O, Bourdette D, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2004;63(11):2039–2045. doi: 10.1212/01.WNL.0000145762.60562.5D.
- Kaufman MD, Johnson SK, Moyer D, Bivens J, Norton HJ. Multiple sclerosis: severity and progression rate in African Americans compared with whites. Am J Phys Med Rehabil. 2003;82(8):582–590.
- Kister I, Chamot E, Bacon JH, et al. Rapid disease course in African Americans with multiple sclerosis. Neurology. 2010;75(3):217–223. doi: 10.1212/WNL.0b013e3181e8e72a.
- Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races? Neurology. 2006;66(8):1235–1240. doi: 10.1212/01.wnl.0000208505.81912.82.
- Weinstock-Guttman B, Ramanathan M, Hashmi K, et al. Increased tissue damage and lesion volumes in African Americans with multiple sclerosis. Neurology. 2010;74(7):538–544. doi: 10.1212/WNL.0b013e3181cff6fb.
- Cree BA, Al-Sabbagh A, Bennett R, Goodin D. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol. 2005;62(11):1681–1683. doi: 10.1001/archneur.62.11.1681.
- Klineova S, Nicholas J, Walker A. Response to disease modifying therapies in African Americans with multiple sclerosis. Ethn Dis. 2012;22(2):221–225.
- Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819–1828. doi: 10.1016/S0140-6736(12)61769-3.
- Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829–1839. doi: 10.1016/S0140-6736(12)61768-1.
- Coles AJ, Cohen JA, Fox EJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology. 2017;89(11):1117–1126. doi: 10.1212/WNL.0000000000004354.
- Havrdova E, Arnold DL, Cohen JA, et al. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology. 2017;89(11):1107–1116. doi: 10.1212/WNL.0000000000004313.
- Ziemssen T, Thomas K. Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord. 2017;10(10):343–359. doi: 10.1177/1756285617722706.
- Comi G, Arnold DL, Boyko AN, et al. Alemtuzumab improves clinical and MRI disease activity outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ study) Mult Scler. 2018;24:S702–S703.
- Singer BA, Alroughani R, Broadley S, et al. Alemtuzumab improves clinical and MRI disease activity outcomes including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS II follow-up (TOPAZ study) Mult Scler. 2018;24:S493–S494.
- LEMTRADA (alemtuzumab) [Prescribing Information]. Genzyme Corporation, USA.
- LEMTRADA [Summary of Product Characteristics] April 2019. Diegem, Belgium: Sanofi Belgium.
- Khan O, Williams MJ, Amezcua L, et al. Multiple sclerosis in US minority populations: clinical practice insights. Neurol Clin Pract. 2015;5(2):132–142. doi: 10.1212/CPJ.0000000000000112.
- Branson RD, Davis K, Jr, Butler KL. African Americans’ participation in clinical research: importance, barriers, and solutions. Am J Surg. 2007;193(1):32–39. doi: 10.1016/j.amjsurg.2005.11.007.
- Wray S, Havrdova E, Snydman DR, et al. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler. 2018:1352458518796675.
- Cuker A, Bass AD, Nadj C, et al. Immune thrombocytopenia in alemtuzumab-treated MS patients: incidence, detection, and management. Mult Scler. 2019:1352458518816612.
- Phelps R, Winston JA, Wynn D, et al. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Mult Scler. 2019:1352458519841829.
- Amezcua L, Rivas E, Joseph S, Zhang J, Liu L. Multiple sclerosis mortality by race/ethnicity, age, sex, and time period in the United States, 1999–2015. Neuroepidemiology. 2018;50(1–2):35–40. doi: 10.1159/000484213.
- Langer-Gould A, Brara SM, Beaber BE, Zhang JL. Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology. 2013;80(19):1734–1739. doi: 10.1212/WNL.0b013e3182918cc2.
- Rivas-Rodriguez E, Amezcua L. Ethnic considerations and multiple sclerosis disease variability in the United States. Neurol Clin. 2018;36(1):151–162. doi: 10.1016/j.ncl.2017.08.007.
- Naismith RT, Trinkaus K, Cross AH. Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review. Mult Scler. 2006;12(6):775–781. doi: 10.1177/1352458506070923.
- Kimbrough DJ, Sotirchos ES, Wilson JA, et al. Retinal damage and vision loss in African American multiple sclerosis patients. Ann Neurol. 2015;77(2):228–236. doi: 10.1002/ana.24308.
- Al-Kawaz M, Monohan E, Morris E, et al. Differential impact of multiple sclerosis on cortical and deep gray matter structures in African Americans and Caucasian Americans. J Neuroimaging. 2017;27(3):333–338. doi: 10.1111/jon.12393.
- Caldito NG, Saidha S, Sotirchos ES, et al. Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study. Brain. 2018;141(11):3115–3129. doi: 10.1093/brain/awy245.
- Howard J, Battaglini M, Babb JS, et al. MRI correlates of disability in African-Americans with multiple sclerosis. PLoS One. 2012;7(8):e43061. doi: 10.1371/journal.pone.0043061.
- Petracca M, Zaaraoui W, Cocozza S, et al. An MRI evaluation of grey matter damage in African Americans with MS. Mult Scler Relat Disord. 2018;25:29–36. doi: 10.1016/j.msard.2018.06.007.
- Buchanan RJ, Martin RA, Wang S, Kim M. Racial analyses of longer-stay nursing home residents with multiple sclerosis. Ethn Dis. 2006;16(1):159–165.
- Ventura RE, Antezana AO, Bacon T, Kister I. Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans. Mult Scler. 2017;23(11):1554–1557. doi: 10.1177/1352458516679894.
- Jeannin S, Deschamps R, Chausson N, Cabre P. Response to interferon-beta treatment in Afro-Caribbeans with multiple sclerosis. Mult Scler Int. 2011;2011:950126.
- Zhovtis Ryerson L, Green R, Confident G, et al. Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic-Americans with multiple sclerosis. Ther Adv Neurol Disord. 2016;9(6):454–461. doi: 10.1177/1756285616661929.
- Cree BA, Stuart WH, Tornatore CS, et al. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. Arch Neurol. 2011;68(4):464–468. doi: 10.1001/archneurol.2011.45.
- Kim H, Lee EJ, Kim SK, Kim KK, Lim YM. Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients. Mult Scler Relat Disord. 2019;30:247–251. doi: 10.1016/j.msard.2019.03.001.
- Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol. 2005;35(11):3332–3342. doi: 10.1002/eji.200535075.
- Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128(2):260–270. doi: 10.1111/j.1365-2567.2009.03115.x.
- Zhang X, Tao Y, Chopra M, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol. 2013;191(12):5867–5874. doi: 10.4049/jimmunol.1301926.
- De Mercanti S, Rolla S, Cucci A, et al. Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. Neurol Neuroimmunol Neuroinflamm. 2016;3(1):e194. doi: 10.1212/NXI.0000000000000194.
- Kim Y, Kim G, Shin HJ, et al. Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis. J Neuroinflamm. 2018;15(1):300. doi: 10.1186/s12974-018-1334-y.
- Lund BT, Traboulsee A, Javed A, et al. Leukocyte repopulation following alemtuzumab treatment in relapsing-remitting MS contains multiple regulatory immune cell types. Mult Scler. 2017;24:S506–S507.
- Gross CC, Ahmetspahic D, Ruck T, et al. Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3(6):e289. doi: 10.1212/NXI.0000000000000289.
Source: PubMed